RISK OF STING POST VENOM IMMUNOTHERAPY

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。此前有报道称，当毒液免疫疗法在5年或更长时间后停止时，在停止治疗后的最初几年内，刺痛反应的风险仍低于10%。一些研究者研究了仅3年后停止治疗，但建议限制，如年轻患者，反应较轻，治疗期间针刺激发阴性或RAST阴性。这项研究的结果将显示患者是否可以在3年后安全地停止治疗，而不是我们目前建议的5-6年，以及在停止治疗后的10年内反应风险是否仍然可以接受。此外，我们将确定在治疗前反应史不太严重的患者或皮肤试验阴性和/或RAST的患者中是否存在较低的风险。 我们继续按照我们的计划，每年刺痛更多的病人。今年，我们有1例患者参加了针刺激发，仅导致局部反应。结果再次继续证明了停止毒液免疫治疗后的良好结果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It has previously been reported that when venom immunotherapy is discontinued after 5 years or more, the risk of a sting reaction remains less than 10% in the first few years after stopping treatment. Some investigators have studied discontinuation of therapy after only 3 years, but have suggested restrictions such as younger patients, milder reactions, and negative sting challenge during therapy or negative RAST. The results of this study will show whether patients can safely stop therapy after only 3 years instead of our current recommendation of 5-6 years, and whether the risk of reaction remains acceptably low in the 10 years after stopping therapy. Also, we will determine whether there is a lower risk in those patients with a less severe history of reaction before treatment or in those who have developed negative skin tests, and/or RAST. We continue to follow our plan of stinging more patients each year. This year we had 1 patient participate in a sting challenge, resulting in a local reaction only. The result again continues to demonstrate the excellent outcome after discontinuing venom immunotherapy.